EMA Authorised: Evoltra (clofarabine) — Sanofi B.V.

View source ↗

Summary

The European Medicines Agency authorised Evoltra (clofarabine) for the treatment of precursor cell lymphoblastic leukemia-lymphoma, with Sanofi B.V. as the mark…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Precursor Cell Lymphoblastic Leukemia-lymphoma

Drugs mentioned

• Evoltra (clofarabine)

Snippet

Status: Authorised. Therapeutic area: Precursor Cell Lymphoblastic Leukemia-Lymphoma. MAH: Sanofi B.V.. Decision date: 17/07/2024